OSSIO News
10 articlesOSSIO Raises $27.6 Million to Accelerate Its Commercial Engine as High Demand for Bio-Integrative Fixation Technology Continues
growth-positive
Ossio Closes $38.5M Series C Financing
Ossio, an orthopedic fixation technology company, has raised $38.5M in Series C funding led by MVM Partners. The funding will be used to strengthen awareness for the patient benefits of OSSIOfiber implants and accelerate new product platforms in the major orthopedic fixation markets. Ossio leverages the OSSIOfiber Intelligent Bone Regeneration Technology to create implants made from a proprietary mineral fiber matrix held together by a naturally degradable polymer. The company has already used over 10,000 OSSIOfiber implants in orthopedic surgeries since 2019.
Investment
OSSIO Announces U.S. Launch and First Commercial Use of OSSIOfiber® Suture Anchors, Expanding Patient Access to Growing Portfolio of Bio-Integrative Orthopedic Fixation Technology
Growth-Positive
OSSIO Achieves Third FDA Clearance in 4 Months for OSSIOfiber® Implants; Prepares to Expand Patient Access to Bio-Integrative Orthopedic Fixation Technology Portfolio in Q2/Q3
Orthopedic fixation technology start-up OSSIO has received its third regulatory clearance from the U.S. Food and Drug Administration (FDA) for its OSSIOfiber product family. The clearance will allow the company to expand patient and surgeon access to additional implants made from OSSIOfiber Intelligent Bone Regeneration Technology over the next six months. The company has already achieved significant market penetration in the United States, with more than 6,000 implantations of OSSIOfiber products performed to date. The recent FDA clearances are expected to increase the uptake of OSSIOs growing portfolio of bio-integrative products.
CustomersExpand
growth-positive
OSSIO Wins GPO Contract for Bio-Integrative Fixation Tech
OSSIO Inc. has expanded its OSSIOfiber product line through a three-year contract with Vizient. The contract enables increased access to OSSIOfiber technology for thousands of U.S. hospitals and surgery centers. The OSSIOfiber products are designed for rapid bone in-growth, regeneration, and replacement, providing durable fixation and natural healing. The contract covers the OSSIOfiber Intelligent Bone Regeneration Technology portfolio, including hammertoe fixation systems, trimmable fixation nails, and compression screws. The products are now available to all members of Vizient at negotiated pricing. OSSIO aims to provide a credible replacement to metal implants in the orthopedic fixation market.
Customers
growth-positive
Ossio gets FDA clearance for OSSIOfiber Hammertoe Fixation System
Orthopaedic fixation company Ossio has received FDA 510(k) market clearance for its OSSIOfiber Hammertoe Fixation System, which maintains alignment and fixation of bone fractures, arthrodesis, osteotomies, and bone grafts. The system, designed in three sizes, utilizes a proprietary natural mineral fiber matrix and bio-integrative material properties to provide a biologically friendly way to restore stability and mobility for patients. Ossio plans to launch the hammertoe fixation system and other OSSIOfiber products over the next year. The companys CEO expressed confidence in achieving excellent clinical outcomes and high surgeon and patient satisfaction. Ossio conducted a multi-center clinical trial in Europe to assess the safety and performance of the system, with positive findings expected to support CE Mark approval later this year.
CustomersInvestment
OSSIO Receives Prestigious Frost & Sullivan New Product Innovation Award for its Breakthrough OSSIOfiberTM Intelligent Bone Regeneration Technology
OSSIO Announces U.S. Launch and First Commercial Use of the New OSSIOfiberTM Bone Pin for Hammertoe Correction
OSSIO Secures $22 Million in Financing
growth-positive
Ossio prepares for US market entrance with new headquarters - 4 details
Ossio, an orthopedic technology company, is preparing to enter the U.S. market this year. The company has established its U.S. corporate headquarters in Woburn, Massachusetts. Ossios CEO, Brian Verrier, has previously operated out of Cummings Executive Suites in Woburn and Beverly, Massachusetts, and has been building up the companys U.S. presence and staff. The companys new lease is for a 3,000-square-foot office at a Cummings Properties business campus. Ossios proprietary OSSIOfiber Intelligent Bone Regeneration technology is an implant used to heal fractured bone.
Expand
